ARTICLE

Relationship Between Anthropometric Factors and Risk of Second Breast Cancer Among Women With a History of Ductal Carcinoma In Situ

Meghan R. Flanagan, Mei-Tzu C. Tang, Michelle L. Baglia, Peggy L. Porter, Kathleen E. Malone, Christopher I. Li

Abstract

Background: Women with ductal carcinoma in situ (DCIS) have an elevated risk of a second breast cancer, but few data are available regarding the impact of modifiable lifestyle factors on this risk.

Methods: In a population-based case–control patient study of women with a history of DCIS in western Washington diagnosed between 1996 and 2013, 497 patients diagnosed with DCIS and a second ipsilateral or contralateral invasive or in situ breast cancer were enrolled. There were 965 matched control patients with one DCIS diagnosis. Associations between anthropometric factors and risk of an invasive or in situ second breast cancer event were evaluated using conditional logistic regression. Statistical tests were two-sided.

Results: Obesity (body mass index [BMI] ≥ 30 kg/m²) at initial DCIS diagnosis was associated with a 1.6-fold (95% confidence interval [CI] = 1.2 to 2.2) increased risk of any second breast cancer and a 2.2-fold increased risk of a contralateral second breast cancer (95% CI = 1.4 to 3.3) compared with normal weight women (BMI < 25 kg/m²). BMI and weight, both at initial DCIS diagnosis and at the time of the second breast cancer diagnosis, were positively associated with risk of any second and second invasive breast cancers (odds ratio = 1.01–1.04, all P < .03).

Conclusions: Although additional confirmatory studies are needed, obesity appears to be an important contributor to the risk of second breast cancers within the growing population of women with DCIS. This has potential clinical relevance with respect to identifying which women with a history of DCIS may require more careful monitoring and who may benefit from lifestyle modifications.

Received: April 10, 2018; Accepted: April 13, 2018

© The Author(s) 2018. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
or die from breast cancer compared with women who are normal or underweight (20–24). Three previous cohort studies have evaluated the association of body mass index (BMI) and second breast events in DCIS patients with inconsistent results (25–27). One study demonstrated increased risk of ipsilateral second breast cancer events in obese patients at initial diagnosis (27), another showed no overall association (23), and a third found that the relationship was modified by menopausal status (28). A key limitation of these three studies was small sample sizes, with the number of second breast cancer events ranging from 76 to 162.

Given the growing population of DCIS survivors, the rising epidemic of obesity in the United States (28), and the paucity of studies that have evaluated the relationship between anthropometric factors and risk of developing a second breast cancer, further investigation is warranted. We examined the relationship between BMI, height, and weight and the risk of second breast cancers in a large population-based study of women with a history of DCIS. The identification of potentially modifiable factors that impact this risk could guide and motivate changes in health behaviors.

Methods

Study Population

We conducted a population-based nested case–control patient study from an underlying cohort of 4157 women age 30–79 years diagnosed with DCIS in the Seattle–Puget Sound region between January 1, 1996, and June 30, 2013 (Supplementary Figure 1, available online). Study participants were identified through the Cancer Surveillance System, a cancer registry serving 13 counties in western Washington State. Participants who underwent bilateral mastectomy were excluded (29,30), as were women who developed nonbreast cancers as treatment could impact the risk of a second breast cancer event. Cases were classified as patients with a second invasive or in situ breast cancer event at least six months following initial diagnosis. Of the 705 eligible case patients, 497 were enrolled (70.5% response rate). Control patients were those diagnosed with DCIS who did not have a second breast cancer event during the study period. Controls were individually matched to case patients on age and year of initial diagnosis (+/-2 years), county of residence, surgical and radiation treatment, histology, grade, and disease-free survival time. All potentially eligible control patients who met matching criteria for a given case patient were assigned a random number and placed in numerical order. Proceeding down the list, two to three control patients per case patient were contacted. Of the 1695 eligible matched control patients, 965 were enrolled (57% response rate). Written, informed consent was obtained from study participants, and the study was approved by the Institutional Review Board at the Fred Hutchinson Cancer Research Center.

Data Collection

Patient demographic, epidemiologic, and clinical data were collected from structured telephone interviews and detailed medical record review. Tumor and treatment data were obtained via medical records. Lifestyle factors such as tobacco and alcohol consumption, reproductive factors, menopausal status, and family history were obtained via interview. Data on weight were collected at initial diagnosis and date of second breast cancer diagnosis for case patients; for control patients, this was the date corresponding to the interval between the first DCIS and second breast cancer diagnosis of the case patient they were matched to. Height was collected at the same time points. Data from medical record review were used as the primary source for anthropometric measures, and when unavailable, interview-based data were used (24%).

Characterization of Exposures

The 49 case patients and 103 control patients with missing BMI (kg/m²) data were excluded, leaving a final analytic data set consisting of 448 case patients and 862 control patients. Results from this case patient–complete analysis were not appreciably different from those completed on the entire study population. Height and weight were evaluated as continuous variables. BMI was categorized as a continuous variable and as a categorical variable using the modified Centers for Disease Control (CDC) classification system (underweight and normal [<25 kg/m²], overweight [25 to 29.9 kg/m²], and obese [≥30 kg/m²]). Changes in BMI and weight between the initial DCIS diagnosis and reference date were also evaluated.

Statistical Analysis

For the primary analysis, control patients were compared with three case patient groups: any second breast event, invasive second breast event, in situ second breast event. Associations between anthropometric factors and these outcomes were estimated using conditional logistic regression given our use of a matched case–control patient design (31). Odds ratios (ORs) and Wald-type 95% confidence intervals were calculated as estimates of relative risks. Effect modification by menopausal status at initial diagnosis, change in menopausal status between initial diagnosis and second breast event/reference date, and receipt of adjuvant endocrine therapy were assessed based on likelihood ratio testing. Because there were no statistically significant interactions with any of the main effects assessed at the prespecified P value of less than .1, no effect modifiers were included in the final models.

Associations between BMI at initial diagnosis with ipsilateral or contralateral second breast cancers were examined in a secondary analysis. One patient with bilateral second breast cancer was excluded. For the analysis of ipsilateral events, patients who underwent a unilateral mastectomy for their initial procedure were excluded.

A sensitivity analysis was performed to assess for significant differences in risk estimates using data from medical record review and interview-based data for our primary exposures. Risk estimates changed less than 10% when analyses were restricted to participants with medical record data, and thus in our final models we included all participants with available data, prioritizing medical record over interview data for anthropomorphic variables.

All models were implicitly adjusted for the case/control patient matching variables given our use of conditional logistic regression. Additionally, we adjusted for menopausal status at initial diagnosis and receipt of adjuvant endocrine therapy as these have been shown to be potential confounders in previous literature (25,26,32). The time period between initial diagnosis and second event (or reference date) varied among some case/control patient pairs (case patients: median = 61 months; control patients: median = 58 months). Consequently, models for
Table 1. Patient, pathology, and treatment characteristics of women with and without a second breast cancer event after initial ductal carcinoma in situ diagnosis

|                               | Controls (n = 862) | Any second breast cancer (n = 448) | Invasive* (n = 303) | In situ† (n = 145) |
|-------------------------------|-------------------|----------------------------------|---------------------|-------------------|
|                               | No. (%)           | No. (%)                          | No. (%)             | No. (%)           |
| **Patient demographics**      |                   |                                  |                     |                   |
| Age at initial diagnosis, y   |                   |                                  |                     |                   |
| Median (IQR)                  | 53 (47–61)        | 53 (47–61)                       | 54 (47–63)          | 52 (47–59)        |
| 30–39                         | 29 (3.4)          | 20 (4.5)                         | 13 (4.3)            | 7 (4.8)           |
| 40–49                         | 274 (31.8)        | 138 (30.8)                       | 92 (30.4)           | 46 (31.7)         |
| 50–59                         | 307 (35.6)        | 156 (34.8)                       | 97 (32.0)           | 59 (40.7)         |
| 60–69                         | 186 (21.6)        | 95 (21.2)                        | 75 (24.8)           | 20 (13.8)         |
| 70+                           | 66 (7.7)          | 39 (8.7)                         | 26 (8.6)            | 13 (9.0)          |
| Year of diagnosis             |                   |                                  |                     |                   |
| 1995–2001                     | 448 (52.0)        | 448 (52.0)                       | 167 (55.1)          | 70 (48.3)         |
| 2002–2007                     | 358 (41.5)        | 358 (41.5)                       | 119 (39.3)          | 62 (42.8)         |
| 2008–2013                     | 56 (6.5)          | 56 (6.5)                         | 17 (5.6)            | 13 (9.0)          |
| Race/ethnicity                |                   |                                  |                     |                   |
| Hispanic                      | 15 (1.7)          | 11 (2.5)                         | 8 (2.6)             | 3 (2.1)           |
| Non-Hispanic white            | 772 (89.6)        | 389 (86.8)                       | 267 (88.1)          | 122 (84.1)        |
| Black                         | 17 (2.0)          | 12 (2.7)                         | 8 (2.6)             | 4 (2.8)           |
| Asian/Pacific Islander        | 45 (5.2)          | 26 (5.8)                         | 12 (4.0)            | 14 (9.7)          |
| Native American               | 13 (1.5)          | 9 (2.0)                          | 7 (2.3)             | 2 (1.4)           |
| Unknown                       | 0                 | 1 (0.2)                          | 1 (0.3)             | 0 (0)             |
| First-degree family history   |                   |                                  |                     |                   |
| No                            | 620 (73.5)        | 300 (68.6)                       | 202 (68.2)          | 98 (69.5)         |
| Yes                           | 223 (26.5)        | 137 (31.4)                       | 94 (31.8)           | 43 (30.5)         |
| Unknown                       | 19                | 11                               | 7                   | 4                 |
| Reproductive characteristics  |                   |                                  |                     |                   |
| No. of full-term pregnancies  |                   |                                  |                     |                   |
| Nulliparous                   | 179 (20.9)        | 101 (22.6)                       | 66 (21.9)           | 35 (24.1)         |
| Parous                        | 677 (79.1)        | 346 (77.4)                       | 236 (78.1)          | 110 (75.9)        |
| Unknown                       | 6                 | 1                                | 1                   | 0                 |
| Age at first live birth‡, y   |                   |                                  |                     |                   |
| <20                           | 87 (10.5)         | 50 (14.9)                        | 38 (16.5)           | 12 (11.4)         |
| 20–24                         | 257 (30.9)        | 133 (39.6)                       | 94 (40.7)           | 39 (37.1)         |
| 25–29                         | 185 (22.2)        | 85 (25.3)                        | 54 (23.4)           | 31 (29.5)         |
| 30–34                         | 84 (10.1)         | 47 (24.0)                        | 31 (13.4)           | 16 (15.2)         |
| ≥35                           | 40 (4.8)          | 21 (6.3)                         | 14 (6.1)            | 7 (6.1)           |
| Unknown                       | 24                | 10                               | 5                   | 5                 |
| Menopausal status at initial DCIS diagnosis | | | | |
| Pre- or perimenopausal        | 340 (40.8)        | 180 (41.3)                       | 115 (39.1)          | 65 (45.8)         |
| Postmenopausal                | 493 (59.2)        | 256 (58.7)                       | 179 (60.9)          | 77 (54.2)         |
| Unknown                       | 29                | 12                               | 9                   | 3                 |
| Menopausal hormone replacement therapy | | | | |
| Never                         | 492 (57.4)        | 492 (57.4)                       | 190 (63.1)          | 87 (60.0)         |
| Former (any type)             | 29 (3.4)          | 29 (3.4)                         | 18 (6.0)            | 5 (3.4)           |
| Current estrogen only         | 182 (21.2)        | 182 (21.2)                       | 56 (18.6)           | 29 (20.0)         |
| Current estrogen and progesterone | 154 (18.0)       | 154 (18)                         | 37 (12.3)           | 24 (16.6)         |
| Unknown                       | 5                 | 2                                | 2                   | 0                 |
| Tumor characteristics         |                   |                                  |                     |                   |
| Histology of initial DCIS*    |                   |                                  |                     |                   |
| Mixed                         | 339 (39.3)        | 155 (34.6)                       | 103 (34.0)          | 52 (35.9)         |
| NOS                           | 210 (24.4)        | 88 (19.6)                        | 63 (20.8)           | 25 (17.2)         |
| Comedo                        | 104 (12.1)        | 67 (15.0)                        | 47 (15.5)           | 20 (13.8)         |
| Cribriform                    | 100 (11.6)        | 58 (12.9)                        | 41 (13.5)           | 17 (11.7)         |
| Solid                         | 73 (8.5)          | 55 (12.3)                        | 35 (11.6)           | 20 (13.8)         |
| Other                         | 36 (4.2)          | 25 (5.6)                         | 14 (4.6)            | 11 (7.6)          |
| Grade of initial DCIS         |                   |                                  |                     |                   |
| 1                             | 20 (2.8)          | 20 (2.8)                         | 13 (5.3)            | 4 (3.4)           |
| 2                             | 210 (29.4)        | 210 (29.4)                       | 63 (25.6)           | 30 (25.6)         |
| 3                             | 223 (31.3)        | 223 (31.3)                       | 70 (28.5)           | 41 (35.0)         |
| 4                             | 259 (36.4)        | 259 (36.4)                       | 100 (40.7)          | 42 (35.9)         |
| Unknown                       | 150               | 85                               | 57                  | 28                |

(continued)
change in BMI were adjusted for number of months between initial diagnosis and reference date. All other covariates in Table 1 were assessed as potential confounders. None were found to change odds ratios more than 10% for continuous or categorical weight, height, or BMI variables, so they were not added to the final multivariable models. To quantify the magnitude of the case–patient differences, we calculated two-sided P heterogeneity values by excluding control patients and comparing different case patient groups. STATA/SE 12.1 (StataCorp LP, College Station, TX) was used for all analyses.

Results

Of the 448 case patients with a second breast cancer event, 303 (67.6%) were invasive and 145 (32.4%) were in situ. The median time between initial DCIS and second breast cancer event (range) was 68 (6–208) months for invasive and 49 (6–213) months for in situ events. Case and control patients groups had similar distributions of age, diagnosis year, race, parity, and menopausal status (Table 1). Patients with invasive second breast cancer events were more likely to have received adjuvant endocrine therapy before initial diagnosis. Patients with any or invasive second breast cancer event were less likely to have received adjuvant endocrine therapy after their initial diagnosis.

Body weight and BMI, both at the time of initial diagnosis and at second diagnosis/reference date, were positively associated with risk of a second breast cancer event (odds ratio = 1.01–1.04, all P < .03) (Table 2). For each 1 mg/kg² increase in BMI at initial DCIS diagnosis, there was a 3% increase in the odds of any second breast cancer event (OR = 1.03, 95% confidence interval [CI] = 1.01 to 1.05). Women who were obese at initial diagnosis had a 1.6-fold (95% CI = 1.2 to 2.2) higher risk of developing a second breast cancer compared with women with a normal BMI. Similar odds were seen for BMI at second diagnosis (OR = 1.01 to 1.04, all P < .03). These risks were more pronounced for invasive vs in situ second breast cancers; however, the differences were not statistically significantly different (initial: P heterogeneity = .61; second: P heterogeneity = .38). Height was not related to risk of second breast cancer.

There were no statistically significant associations observed with gain or loss of BMI and second breast cancer event (Table 3). There was a suggestion of increased risk with BMI loss of ≥3 kg/m² or more for any, invasive, and in situ second breast events, but this was not significant.

After exclusion of four unilateral mastectomy patients and one bilateral recurrence, there were 173 ipsilateral (39.0%) and 270 contralateral (60.8%) second breast cancers. Most ipsilateral (74.0%) and contralateral (63.3%) second breast events were invasive. There was no association between initial BMI and ipsilateral second breast cancer events among all women (Table 4), or those with invasive second breast cancer events (data not shown). However, there was a 2.2-fold (95% CI = 1.4 to 3.3) increased risk of a contralateral second breast cancer associated with obese BMI at initial diagnosis, and there was increased risk associated with both overweight and obese BMI at the second breast cancer event (overweight: OR = 1.6, 95% CI = 1.1 to 2.4; obese: OR = 1.9, 95% CI = 1.3 to 2.6). There was a statistically significantly elevated risk of a contralateral breast cancer event associated with a decrease in BMI of 3 kg/m² or more (OR = 2.0, 95% CI = 1.1 to 3.6), which was the only statistically significant risk difference between ipsilateral and contralateral case patients (P heterogeneity = .01). Among women with invasive contralateral second breast cancer events, there was an approximately twofold increased risk associated with obesity at both the first and second events, as well as with a BMI loss of 3 kg/m² or more (data not shown).

Discussion

The population of women with a history of DCIS has grown as incidence rates have risen steadily over the past several
Table 2. Risk of second breast cancer event in relation to anthropometric factors at initial ductal carcinoma in situ diagnosis and reference date

| Anthropometric Factor | Initial Diagnosis | Second breast event/reference date |
|-----------------------|-------------------|-----------------------------------|
|                       | Controls (n = 862) | Any second breast cancer* (n = 448) | Invasive* (n = 303) | In situ* (n = 145) |
| BMI, mean (SD), kg/m² | 26.5 (6.13)       | 27.2 (6.41) | 0.007 | 27.2 (6.41) | 0.04 (1.01 to 1.1)† | 0.05 | 26.8 (6.69) | 1.01 (0.9 to 1.05) |
|                       | 25.0–29.9         | 1.03 (1.01 to 1.1)† |                       |                       |                      |                       |                       |
| BMI categories, kg/m² | .007              |                      |                   |                       |                       |                       |                       |
| <25.0                 | 255 (29.6)        | 124 (40.9) | 1.0 (ref) | 124 (40.9) | 1.0 (ref) | 62 (42.8) | 1.0 (ref) |                       |
| ≥30.0                 | 190 (22.0)        | 89 (29.4) | 1.3 (0.9 to 1.9)  | 90 (29.7) | 1.8 (1.2 to 2.6)† | 39 (26.9) | 1.3 (0.8 to 2.3)  |                       |
| Height, mean (SD), cm | 164 (6.8)         | 165 (6.8) | 1.0 (0.9 to 1.03) | 165 (6.8) | 1.0 (0.9 to 1.04) | 164 (7.0) | 1.0 (0.9 to 1.1)  |                       |
| Height, quartiles, m  | 1.0 (ref)         | 1.0 (1.0 to 1.02)† | .123             |                      |                       |                       |                       |
| 130–160               | 278 (32.3)        | 91 (30)  | 1.0 (ref) | 48 (33.1) | 1.0 (ref) |                       |                       |                       |
| 161–164               | 179 (20.8)        | 61 (20.1) | 1.0 (0.7 to 1.5)  | 27 (18.6) | 0.9 (0.5 to 1.7)  |                       |                       |                       |
| 165–168               | 213 (24.7)        | 67 (22.1) | 1.0 (0.6 to 1.5)  | 31 (21.4) | 0.8 (0.5 to 1.5)  |                       |                       |                       |
| 169–188               | 192 (22.3)        | 84 (27.7) | 1.4 (0.9 to 2.1)  | 39 (26.9) | 1.2 (0.7 to 2.2)  |                       |                       |                       |
| Weight, mean (SD), kg | 70.9 (16.7)       | 74.5 (17.6) | 1.01 (1.00 to 1.02)† | 73.4 (19.5) | 1.01 (0.99 to 1.02) | .349             |                       |                       |
| Weight, quartiles, kg | 1.0 (ref)         | 1.01 (1.00 to 1.02)† | .002             |                      |                       |                       |                       |                       |
| 37.2–59.9             | 231 (26.8)        | 58 (19.1) | 1.0 (ref) | 38 (26.2) | 1.0 (ref) |                       |                       |                       |
| 60.0–68.9             | 239 (27.7)        | 82 (27.1) | 1.3 (0.9 to 2.0)  | 37 (25.5) | 0.8 (0.5 to 1.4)  |                       |                       |                       |
| 69.0–80.9             | 201 (23.3)        | 63 (20.8) | 1.3 (0.8 to 2.1)  | 31 (21.4) | 0.9 (0.5 to 1.8)  |                       |                       |                       |
| 81.0–168.3            | 191 (22.2)        | 100 (33.0) | 2.2 (1.4 to 3.4)† | 39 (26.9) | 1.1 (0.6 to 2.1)  |                       |                       |                       |
| BMI, mean (SD), kg/m² | 26.5 (6.3)        | 27.6 (6.3) | 1.03 (1.00 to 1.04)† | 27.1 (6.5) | 1.01 (0.97 to 1.05) | .698             |                       |                       |
| BMI categories, kg/m² | .028              |                      |                   |                       |                       |                       |                       |                       |
| <25.0                 | 388 (45.0)        | 106 (35.0) | 1.0 (ref) | 56 (38.6) | 1.0 (ref) |                       |                       |                       |
| ≥30.0                 | 263 (30.5)        | 106 (35.0) | 1.8 (1.3 to 2.7)† | 48 (33.1) | 0.9 (0.6 to 1.5)  |                       |                       |                       |
| Weight, mean (SD), kg | 71.9 (17.5)       | 75.4 (17.4) | 1.01 (1.00 to 1.02)† | 74.0 (18.7) | 1.00 (0.90 to 1.02) | .509             |                       |                       |
| Weight quartiles, kg  | .008              |                      |                   |                       |                       |                       |                       |                       |
| 42.0–60.9             | 212 (24.6)        | 63 (20.8) | 1.0 (ref) | 40 (27.6) | 1.0 (ref) |                       |                       |                       |
| 61.0–69.0             | 248 (28.8)        | 57 (18.8) | 0.8 (0.5 to 1.2)  | 30 (20.7) | 0.6 (0.4 to 1.2)  |                       |                       |                       |
| 69.1–81.9             | 211 (24.5)        | 93 (30.7) | 1.7 (1.1 to 2.8)† | 33 (22.8) | 0.8 (0.4 to 1.4)  |                       |                       |                       |
| 82.0–172.8            | 191 (22.2)        | 90 (29.7) | 1.6 (1.04 to 2.6)† | 42 (29.0) | 1.1 (0.6 to 1.9)  |                       |                       |                       |

*Odds ratios and 95% confidence intervals were estimated using conditional logistic regression and were implicitly adjusted for matching variables (age and year of the initial DCIS diagnosis, county, histology, grade of initial DCIS lesion, surgical and radiation treatment, and survival time). All models were additionally adjusted for menopausal status at initial DCIS diagnosis and use of adjuvant endocrine therapy. BMI = body mass index; CI = confidence interval; OR = odds ratio.

†P < .05.

 decades. These women have an elevated risk of developing a subsequent breast cancer, but relatively little is known regarding how modifiable lifestyle factors influence this risk. Of particular importance is obesity given the continued rise in obesity rates and previously established links between obesity and invasive breast cancer (20–24). Our results indicate that the relationship between BMI and second primary breast events among DCIS survivors is complex, with variation across levels of BMI and possibly according to stage and laterality.

Few studies have evaluated the impact of anthropometric factors on second breast cancer events after DCIS, and they had inconsistent results. In a population-based cohort study including 480 patients from 1980 to 1992, Habel et al. evaluated the risk of invasive or in situ ipsilateral second breast cancers or metastases among breast conservation patients (27). Based on 76 ipsilateral events, obesity was associated with a twofold increased risk of ipsilateral second breast cancer compared with women with a BMI of less than 22 kg/m². Kuerer et al. also combined invasive and in situ events, but presented associations stratified by laterality. Consistent with our findings, but contrasting those of Habel et al., they found no association with risk of an ipsilateral second breast cancer in a single-institution cohort study (n = 1885) with 40 ipsilateral events (25). A potential explanation for these differences is variation in DCIS treatment. Receipt of radiation therapy is associated with decreased risk of ipsilateral second breast cancers (5). In the Kuerer et al. study, 80% of patients received adjuvant radiation compared with 55% in our study and 40% in Habel et al. Adjuvant tamoxifen therapy also decreases the risk of second breast cancer events (17,33). This was used by approximately one-third of patients in Kuerer et al. and our study but was not routinely used during the time frame of Habel et al.
Although Kuerer et al. found no statistically significant differences in the risk of ipsilateral second breast events according to BMI, a univariate analysis of their data revealed a borderline significantly ($P = .06$) elevated risk of contralateral second breast cancers associated with overweight/obesity among women who did not receive adjuvant tamoxifen therapy. No multivariable analysis was presented. In our analysis adjusted for adjuvant endocrine therapy, there were no statistically significant
differences in risk of ipsilateral or contralateral second breast cancers; however, there was a suggestion of increased contralateral risk associated with obesity at both initial and second diagnosis. Both studies were likely underpowered to detect statistically significant associations, and further studies with longer follow-up and larger numbers of contralateral breast cancers are needed to confirm our finding of a possible association between obesity and contralateral breast cancer risk.

McLaughlin et al. conducted the largest examination of BMI and second breast cancer events in a DCIS population \( (n = 1925) \). In contrast to our study, they did not observe increased risk of second breast cancer events associated with increasing BMI before initial diagnosis \( (HR = 0.99, 95\% CI = 0.96 to 1.02) \) or between initial and subsequent diagnosis \( (HR = 1.03, 95\% CI = 0.97 to 1.10) \) in the overall cohort. However, they found that menopausal status at initial diagnosis modified the effect of obesity on the risk of second breast cancer events \( (26) \).

Premenopausal women who were obese at diagnosis were 77% less likely to develop any second breast cancer compared with normal and underweight women, whereas a non-statistically significant trend toward increased risk associated with overweight and obesity was seen in postmenopausal women. We did not find evidence of effect modification according to menopausal status in our study, but in their analysis of premenopausal women, there were only four obese patients with second breast cancer events \( (\text{compared with 39 in our study}) \), limiting the statistical power and generalizability of their findings.

One finding unique to our study was the increased risk of a contralateral second breast cancer event associated with a substantial loss of BMI after initial diagnosis, but no increased risk associated with weight gain. McLaughlin et al. evaluated change in weight, and also did not observe an association between weight gain and risk of second breast cancer events \( (26) \). In contrast to our study, they also found no association with loss of BMI. Although there is a dearth of information about weight change after DCIS, a number of studies have investigated this relationship after an invasive cancer diagnosis \( (34–43) \). These studies have shown conflicting results, with several reporting an increased risk of second breast cancers associated with weight gain \( (37,41) \), others demonstrating no association \( (35) \), and another offering evidence of a relationship between substantial weight loss and increased risk of second breast cancer \( (43) \). Mechanisms explaining associations between weight loss and second breast cancers are lacking but may involve compromised tumor–immune system interactions accompanying chronic undernutrition \( (44) \) or dysfunctional mammary adipocytes \( (45,46) \). Whether our results suggest that avoidance of major weight loss subsequent to a DCIS diagnosis may be an additional approach to reduce the risk of second breast cancer events or if this is merely a reflection of cachexia associated with a second breast cancer event is unclear and requires additional study.

One of the strengths of our study is its population-based nested case–control patient design, which is well suited to studying rare diseases such as second cancer events that require many years of follow-up for detection. This is only the fourth published study to assess the relationship between BMI and risk of second breast cancer events after a diagnosis of DCIS, and our sample size is appreciably larger than any of the prior studies. Further, the population-based nature of our study makes it potentially more generalizable than single-institution series.

The primary potential limitation of our study is recall bias. However, data for our primary exposures of interest were largely abstracted from medical records and not subject to recall bias. For those patients missing BMI data, there may be bias that we cannot account for in our models. There was no difference with respect to patient demographic, lifestyle, and tumor characteristics compared with patients without missing data, and the degree and direction of bias are unknown. An additional limitation is lack of data on other modifiable risk factors, particularly physical activity. However, data on this subject in DCIS are lacking. However, data from a large meta-analysis including 11 cohort and eight case–control patient studies found no differential effects of physical activity on invasive breast cancer risk according to BMI \( (47) \). Therefore, we would not expect physical activity to significantly confound or modify our findings.

Participation bias is another potential concern, but we did achieve reasonable response rates for a study of this type, which limits the impact of this bias. During the time frame including many of the initial DCIS diagnoses, hormone receptors were not routinely tested. Therefore, there is a substantial amount of missing data for this variable, and we were unable to include this as a matching variable, effect modifier, or confounder. Finally, although our results suggest that there may be increased risk of invasive and contralateral second breast cancer events associated with increasing BMI, the study lacked power to show significant heterogeneity. Larger studies are needed to confirm our findings.

Few studies have evaluated the influence of potentially modifiable lifestyle factors on the risk of subsequent breast cancers among women with DCIS. Second breast cancers are an important outcome for this population, as women with DCIS have a two to four times greater risk of developing a second breast cancer than women in the general population have of developing a first breast cancer. Additionally, a second invasive event is associated with a 1.75-fold increased mortality risk \( (12) \). Our findings suggest that obesity is positively related to second breast cancer events, and possibly more strongly with invasive and contralateral second cancers. Efforts to maintain a normal weight have well-known health benefits for a variety of diseases, and this may also extend to lowering risk of a second breast cancer among women diagnosed with DCIS. Further research is needed on the types of exercise/dietary interventions that could be effective among DCIS survivors.

Funding

MRF was supported by T32 grant support from the National Institutes of Health under award number CA009168. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Notes

Affiliations of authors: Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (MRF, MTCT, MLB, PLP, KEM, CIL); Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY (MRF).

There are no potential conflicts of interest.

References

1. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62.
2. Kreilkowke K. Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010;2010(41):139–141.
3. Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: A meta-analysis. Cancer. 1999;85(3):616–628.

4. Stuart KE, Houssami N, Taylor R, Hayen A, Boyages J. Long-term outcomes of ductal carcinoma in situ of the breast: A systematic review, meta-analysis and meta-regression analysis. BMC Cancer. 2015;15(1):890.

5. Early Breast Cancer Trialists’ Collaborative Group, Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 9,355 women. Lancet. 2011;378(9785):1703–1714.

6. Van Zee KJ, Subbedar P, Olicse C, Patil S, Morrow M. Relationship between margin width and recurrence of ductal carcinoma in situ: Analysis of 2996 women treated with breast-conserving surgery for 30 years. Ann Surg. 2015;262(4):623–633.

7. Virmu RA, Tuttle TM, Samihlyan T, Kane RL. Ductal carcinoma in situ of the breast: A systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102(9):170–178.

8. Li CT, Arun BK, Daling JR. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988–2001. Cancer. 2006;106(10):2104–2112.

9. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: A trial of the Eastern Cooperative Oncology Group. J Natl Cancer Inst. 2009;27(3):5319–5324.

10. Wärnberg F, Bergh J, Zack M, Holmberg L. Risk factors for subsequent invasive breast cancer and breast cancer death after ductal carcinoma in situ: A population-based case-control study in Sweden. Cancer Epidemiol Biomarkers Prev. 2001;10(5):495–499.

11. Donker M, Litte`re S, Werutsky G, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10835 randomized phase III trial. J Clin Oncol. 2013;31(3):406–410.

12. Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(6):478–488.

13. Wang S-Y, Chin C-H, Inglesby T, et al. Network meta-analysis of margin threshold for women with ductal carcinoma in situ. J Natl Cancer Inst. 2012;104(7):507–516.

14. Rudloff U, Brog I, Reiner AS, et al. The influence of margin width and volume of near margin on benefit of radiation therapy for women with DCIS treated with breast-conserving therapy. Ann Surg. 2010;251(4):583–591.

15. Habel LA, Moe RE, Daling JR. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988–2001. Cancer. 2006;106(10):2104–2112.

16. Rawal R, Lorenzo Bermejo J, Hemminki K. Risk of subsequent invasive breast cancer among women diagnosed with estrogen receptor-positive in situ breast cancer. Breast Cancer Res Treat. 2010;123(3):627–635.

17. Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with ductal carcinoma in situ: A meta-analysis. Cancer Epidemiol Biomarkers Prev. 2011;20(6):1327–1334.

18. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol. 2011;29(17):2230–2235.

19. Caan BJ, Emond JA, Natarajan L, et al. Post-diagnosis weight gain and breast cancer: Systematic review and meta-analysis. J Natl Cancer Inst. 2011;103(6):478–488.

20. Schouten van der Velden AP, van Vught V, Van Dijck JAAM, Leer JWH, Wobbes T. Local recurrences after different treatment strategies for ductal carcinoma in situ of the breast: A population-based study in the East Netherlands. J Radiat Oncol Biol Phys. 2007;69(9):703–710.

21. Breslow NE, Day NE. Statistical Methods in Cancer Research: The Analysis of Case-Control Studies. Version 1, Scientific Publication 32. Lyon: International Agency for Research on Cancer, 1980.

22. Fisher B, Dignam J, Wolsmark C, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353(9169):1993–2000.

23. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol. 2011;29(17):2230–2235.

24. Greenlee R, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50(1):7–33.

25. Trentham-Dietz A, Newcomb PA, Nichols HB, Hampton JM. Breast cancer risk factors and secondary primary malignancies among women with breast cancer. Breast Cancer Res Treat. 2007;105(2):195–207.

26. Kuerer HM, Lari SA, Arun BK, et al. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat. 2012;133(3):1131–1141.

27. McLaughlin VH, Trentham-Dietz A, Hampton JM, Newcomb PA, Sprague BL. Lifestyle factors and the risk of ductal breast cancer among women diagnosed with ductal carcinoma in situ. Cancer Epidemiol Biomarkers Prev. 2014;23(3):450–460.

28. Pimentel-Ramos K, Wirtschafter J, Berenson G. Effect of mammographic screening on breast cancer incidence and mortality in women: A systematic review and meta-analysis. J Natl Cancer Inst. 2009;101(1):30–42.

29. Kuske BR, Yantosca RM, Cederholm GJ, Bolton JS, Fineberg BB. The influence of young age and positive family history of breast cancer on the prognosis of ductal carcinoma in situ treated by excision with or without radiation therapy or by mastectomy. Int J Radiat Oncol Biol Phys. 2000;48(4):915–921.

30. Schouten van der Velden AP, van Vught V, Van Dijck JAAM, Leer JWH, Wobbes T. Local recurrences after different treatment strategies for ductal carcinoma in situ of the breast: A population-based study in the East Netherlands. J Radiat Oncol Biol Phys. 2007;69(9):703–710.

31. Breslow NE, Day NE. Statistical Methods in Cancer Research: The Analysis of Case-Control Studies. Version 1, Scientific Publication 32. Lyon: International Agency for Research on Cancer, 1980.

32. Fisher B, Dignam J, Wolsmark C, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353(9169):1993–2000.

33. Wapnir IL, Dignam J, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(6):478–488.

34. Goodwin PJ, Ennis M, Pritchard KI, et al. Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol. 1999;17(1):120–129.

35. Caan BJ, Emond JA, Natarajan L, et al. Post-diagnosis weight gain and breast cancer recurrence in women with early stage breast cancer. Breast Cancer Res Treat. 2006;99(1):47–57.

36. Chlebowski RT, Weaver JK, Reynolds R, Luce J, Bulcavage L, Batenar J. Long-term survival following relapse after 5-FU but not CMF adjuvant breast cancer therapy. Breast Cancer Res Treat. 1986;7(1):23–30.

37. Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krock JE, Veeder MH. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol. 1990;8(8):1327–1334.

38. Heasman KZ, Sutherland HJ, Campbell JA, Elbakim T, Boyd NF. Weight gain during adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 1985;5(3):195–200.

39. Goodwin PJ, Fanzarella T, Boyd NF. Weight gain in women with localized breast cancer—a descriptive study. Breast Cancer Res Treat. 1988;11(1):59–66.

40. Croenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol. 2005;23(7):1370–1378.

41. Levine EG, Racaynski JM, Carpenter JT. Weight gain with breast cancer adjuvant chemotherapy. Ann Oncol. 2005;16(5):720–725.

42. Levine EG, Racaynski JM, Carpenter JT. Weight gain with breast cancer adjuvant chemotherapy. Breast Cancer Res Treat. 2011;125(3):1327–1334.

43. Caan BJ, Emond JA, Natarajan L, et al. Post-diagnosis weight gain and breast cancer recurrence in women with early stage breast cancer. Breast Cancer Res Treat. 2006;99(1):47–57.